NK-92MI; Natural Killer Cell; Human (Homo sapiens) Item ID: ATCCRL2408
| Permits and Restrictions |
View Permits View Restrictions |
|---|---|
| Organism | Homo sapiens, human |
| Tissue | peripheral blood, blood |
| Cell Type | natural killer cell; NK cell |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension, multicell aggregates |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | malignant non-Hodgkin's lymphoma |
| Age | 50 years |
| Gender | male |
| Ethnicity | Caucasian |
| Applications | The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. |
| Storage Conditions | liquid nitrogen vapor phase |
| Images | |
|---|---|
| Derivation | NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92 (ATCC CRL-2407) cell line by transfection. NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable. |
| Clinical Data | male 50 years Caucasian |
| Comments |
NK-92 and this derivative cell line NK-92MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR.
The parental IL-2 dependent cell line is available as ATCC CRL-2407 (NK-92). NK-92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative. ATCC confirmed this cell line is positive for the presence of Epstein-Barr viral DNA sequences via PCR. |
| Complete Growth Medium | The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%. |
|---|---|
| Subculturing |
Cultures can be maintained by centrifuging cells and resuspending cell pellet in fresh medium at 2 - 3 x 105 viable cells/mL. Centrifugation and full replacement of culture medium may be performed for the first subcultures. Cultures can then be maintained by addition of fresh medium. These cells tend to grow in aggregates that may lose viability when they are dispersed. Accurate counts and viabilities may not be possible. Maintain cell density between 2 x 105 and 1 x 106 viable cells/mL or use a 1:3 spilt ratio. |
| Cryopreservation | Freeze medium: FBS, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | D5S818: 12. 13 D13S317: 9, 12 D7S820: 10, 11 D16S539: 11, 12 vWA: 16, 18 THO1: 6, 9.3 TPOX: 8 CSF1PO: 11, 12 Amelogenin: X, Y |
|---|
| Name of Depositor | NantKwest Inc. |
|---|---|
| Year of Origin | 1998 |
| References |
Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260 Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666 Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052 |